Fundraising FoxSeraxis
Germantown, US · Founded 2021 · 6 known investors
Find your way into Seraxis
Sign up to see every warm intro you have to Seraxis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Seraxis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients. It pursues scientific collaborations and licensing partnerships around its cell therapy technologies.
Founders & leadership
Seraxis was founded in 2021 by William L. Rust.
Board
Investors · 6
How we know: Frazier Life Sciences's portfolio page · board seat on SEC Form D · biopharmadive.com · Not right? Tell us
How we know: Maryland TEDCO's portfolio page · Not right? Tell us
How we know: biopharmadive.com · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$24M disclosed across 2 of 5 rounds · 2016–2026
- Undisclosed amountsecond round of venture capital financingSep 2023
Eli Lilly, Frazier Life Sciences, JDRF T1D Fund, Polaris Partners
Source ↗ - Undisclosed amountSeries BAug 2016Source ↗
▶$10MraisedSep 2026 · 1 investors · BiotechnologyRule 506(b)
- William L. RustExecutive Officer, Director
- Carole WelschExecutive Officer
- Jerry BatyDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$14MraisedFeb 2021 · 5 investors · OtherRule 506(b)
- Gi-Hyeok YangDirector
- James N. TopperDirector
- Carole WelschExecutive Officer
- William L. RustExecutive Officer, Director, Promoter
- Roy ArupDirector
- Bernie TreidlDirector
- Offering amount
- $40M
- Amount sold
- $14M
- Finders' fees
- $849.5K
- Placement agents
- Capstone Headwaters
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Seraxis.
In the news
Frequently asked questions
- What does Seraxis do?
- Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients. It pursues scientific collaborations and licensing partnerships around its cell therapy technologies.
- Who founded Seraxis?
- Seraxis was founded by William L. Rust in 2021.
- Who are Seraxis's investors?
- Seraxis's investors include Frazier Life Sciences, Maryland TEDCO, TEDCO, JDRF T1D Fund.
- How much funding has Seraxis raised?
- Seraxis has disclosed $24M raised across 2 of its 5 known rounds.
- Where is Seraxis headquartered?
- Seraxis is headquartered in Germantown, US.